Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.55
CRIS's Cash to Debt is ranked lower than
68% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. CRIS: 2.55 )
Ranked among companies with meaningful Cash to Debt only.
CRIS' s Cash to Debt Range Over the Past 10 Years
Min: 1.68  Med: 7.98 Max: No Debt
Current: 2.55
Equity to Asset 0.57
CRIS's Equity to Asset is ranked lower than
62% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRIS: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
CRIS' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.7 Max: 0.95
Current: 0.57
0.12
0.95
F-Score: 3
Z-Score: -13.09
M-Score: -4.45
WACC vs ROIC
21.30%
-940.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -833.98
CRIS's Operating margin (%) is ranked lower than
76% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. CRIS: -833.98 )
Ranked among companies with meaningful Operating margin (%) only.
CRIS' s Operating margin (%) Range Over the Past 10 Years
Min: -833.98  Med: -88.52 Max: -35.24
Current: -833.98
-833.98
-35.24
Net-margin (%) -861.75
CRIS's Net-margin (%) is ranked lower than
76% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CRIS: -861.75 )
Ranked among companies with meaningful Net-margin (%) only.
CRIS' s Net-margin (%) Range Over the Past 10 Years
Min: -861.75  Med: -89.44 Max: -27.72
Current: -861.75
-861.75
-27.72
ROE (%) -111.47
CRIS's ROE (%) is ranked lower than
82% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. CRIS: -111.47 )
Ranked among companies with meaningful ROE (%) only.
CRIS' s ROE (%) Range Over the Past 10 Years
Min: -125.1  Med: -28.4 Max: -11.29
Current: -111.47
-125.1
-11.29
ROA (%) -73.28
CRIS's ROA (%) is ranked lower than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. CRIS: -73.28 )
Ranked among companies with meaningful ROA (%) only.
CRIS' s ROA (%) Range Over the Past 10 Years
Min: -74.86  Med: -22.89 Max: -10.23
Current: -73.28
-74.86
-10.23
ROC (Joel Greenblatt) (%) -16255.18
CRIS's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CRIS: -16255.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRIS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -16255.18  Med: -1428.04 Max: -206.43
Current: -16255.18
-16255.18
-206.43
Revenue Growth (3Y)(%) -33.20
CRIS's Revenue Growth (3Y)(%) is ranked lower than
81% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CRIS: -33.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRIS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.7  Med: 0.75 Max: 76.3
Current: -33.2
-39.7
76.3
EBITDA Growth (3Y)(%) 30.20
CRIS's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CRIS: 30.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRIS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.4  Med: -10.8 Max: 30.2
Current: 30.2
-49.4
30.2
EPS Growth (3Y)(%) 31.70
CRIS's EPS Growth (3Y)(%) is ranked higher than
85% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CRIS: 31.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRIS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.5  Med: -13.5 Max: 35.7
Current: 31.7
-74.5
35.7
GuruFocus has detected 3 Warning Signs with Curis Inc $CRIS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CRIS Guru Trades in Q4 2015

Steven Cohen 1,192,900 sh (+7.97%)
Paul Tudor Jones 18,963 sh (unchged)
First Eagle Investment 24,008,672 sh (unchged)
Jim Simons 90,300 sh (-30.27%)
» More
Q1 2016

CRIS Guru Trades in Q1 2016

Paul Tudor Jones 18,963 sh (unchged)
First Eagle Investment 24,008,672 sh (unchged)
Steven Cohen 1,100,000 sh (-7.79%)
Jim Simons 38,700 sh (-57.14%)
» More
Q2 2016

CRIS Guru Trades in Q2 2016

Jim Simons 39,400 sh (+1.81%)
Paul Tudor Jones 18,963 sh (unchged)
Steven Cohen 1,100,000 sh (unchged)
First Eagle Investment 24,008,672 sh (unchged)
» More
Q3 2016

CRIS Guru Trades in Q3 2016

Jim Simons 143,300 sh (+263.71%)
Steven Cohen 1,100,200 sh (+0.02%)
Paul Tudor Jones 18,963 sh (unchged)
First Eagle Investment 24,008,672 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:AKBA, NAS:NVAX, NAS:LJPC, NAS:BSTC, NAS:NSTG, NAS:NERV, NAS:CCXI, NAS:TLGT, NAS:SPPI, NAS:FOMX, NAS:XBIT, NAS:MYOK, NAS:MRUS, NAS:NOVN, NAS:PDLI, NAS:TRVN, NAS:CLDX, AMEX:BTX, NAS:MACK, NAS:OMER » details
Traded in other countries:CUS.Germany,
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.

Curis Inc was organized as a Delaware corporation on February 14, 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a drug discovery and development company that leverages its signaling pathway drug technologies to develop next generation targeted cancer therapies. The Company's advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. The Company has in the U.S., 93 issued or allowed patents. The Company's competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is. The Company is subject to government regulations.

Ratios

vs
industry
vs
history
P/B 9.59
CRIS's P/B is ranked lower than
84% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. CRIS: 9.59 )
Ranked among companies with meaningful P/B only.
CRIS' s P/B Range Over the Past 10 Years
Min: 1.15  Med: 4.15 Max: 12.44
Current: 9.59
1.15
12.44
P/S 46.43
CRIS's P/S is ranked lower than
76% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. CRIS: 46.43 )
Ranked among companies with meaningful P/S only.
CRIS' s P/S Range Over the Past 10 Years
Min: 2.4  Med: 14.29 Max: 382
Current: 46.43
2.4
382
Current Ratio 4.54
CRIS's Current Ratio is ranked higher than
53% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CRIS: 4.54 )
Ranked among companies with meaningful Current Ratio only.
CRIS' s Current Ratio Range Over the Past 10 Years
Min: 2.89  Med: 7.64 Max: 25.89
Current: 4.54
2.89
25.89
Quick Ratio 4.54
CRIS's Quick Ratio is ranked higher than
55% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CRIS: 4.54 )
Ranked among companies with meaningful Quick Ratio only.
CRIS' s Quick Ratio Range Over the Past 10 Years
Min: 2.89  Med: 7.64 Max: 25.89
Current: 4.54
2.89
25.89
Days Sales Outstanding 93.40
CRIS's Days Sales Outstanding is ranked lower than
69% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. CRIS: 93.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRIS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.04  Med: 20.73 Max: 97.57
Current: 93.4
1.04
97.57
Days Payable 4.00
CRIS's Days Payable is ranked lower than
91% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. CRIS: 4.00 )
Ranked among companies with meaningful Days Payable only.
CRIS' s Days Payable Range Over the Past 10 Years
Min: 4  Med: 3773.12 Max: 5192.95
Current: 4
4
5192.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
CRIS's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. CRIS: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRIS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -8.85 Max: -3.7
Current: -17.3
-43.8
-3.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.44
CRIS's Price/Net Cash is ranked lower than
74% of the 516 Companies
in the Global Biotechnology industry.

( Industry Median: 5.83 vs. CRIS: 14.44 )
Ranked among companies with meaningful Price/Net Cash only.
CRIS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.78  Med: 6.5 Max: 21.58
Current: 14.44
1.78
21.58
Price/Net Current Asset Value 13.00
CRIS's Price/Net Current Asset Value is ranked lower than
76% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 5.63 vs. CRIS: 13.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRIS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.78  Med: 6.17 Max: 16.62
Current: 13
1.78
16.62
Price/Tangible Book 12.62
CRIS's Price/Tangible Book is ranked lower than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CRIS: 12.62 )
Ranked among companies with meaningful Price/Tangible Book only.
CRIS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.64  Med: 5.49 Max: 15.64
Current: 12.62
1.64
15.64
Price/Median PS Value 3.25
CRIS's Price/Median PS Value is ranked lower than
91% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. CRIS: 3.25 )
Ranked among companies with meaningful Price/Median PS Value only.
CRIS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 1.16 Max: 22.57
Current: 3.25
0.1
22.57
Earnings Yield (Greenblatt) (%) -18.70
CRIS's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CRIS: -18.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRIS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.24  Med: 0.8 Max: 1.1
Current: -18.7
-19.24
1.1

More Statistics

Revenue (TTM) (Mil) $7.26
EPS (TTM) $ -0.48
Beta2.60
Short Percentage of Float4.41%
52-Week Range $1.25 - 3.72
Shares Outstanding (Mil)140.55

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 7 8 7 7
EPS ($) -0.46 -0.47 -0.46 -0.43
EPS w/o NRI ($) -0.46 -0.47 -0.46 -0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CRIS

Headlines

Articles On GuruFocus.com
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
First Eagle Increases Holdings of Spin-Off and Cancer Drug Company Mar 10 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 14 2013 
Weekly CFO Sells Highlight: USB, GNC, WWWW, GWRE, CRIS, CSL Apr 30 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 
Curis Inc. Reports Operating Results (10-Q) Aug 03 2010 
Jean-Marie Eveillard Buys More Curis Inc. Aug 11 2009 
Curis Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Curis, Inc. – Value Analysis (NASDAQ:CRIS) : January 13, 2017 Jan 13 2017
Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : January 12, 2017 Jan 12 2017
Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration Jan 09 2017
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 06 2017
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 06 2017
ETFs with exposure to Curis, Inc. : December 27, 2016 Dec 27 2016
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance Dec 21 2016
How Arlington Asset Investment Corp (AI) Stacks Up Against Its Peers Dec 15 2016
CURIS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 14 2016
Hedge Funds Are Selling Curis, Inc. (CRIS) Dec 12 2016
Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : December 12, 2016 Dec 12 2016
ETFs with exposure to Curis, Inc. : December 8, 2016 Dec 08 2016
Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : December 1, 2016 Dec 01 2016
Curis Announces Full Approval of Roche’s Erivedge® in the European Union Nov 28 2016
ETFs with exposure to Curis, Inc. : November 23, 2016 Nov 23 2016
Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors Nov 14 2016
CURIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Nov 14 2016
Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors Nov 14 2016
Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A? Nov 10 2016
ETF’s with exposure to Curis, Inc. : November 9, 2016 Nov 09 2016
CURIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 09 2016
Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at... Nov 09 2016
CURIS INC Financials Nov 08 2016
Curis Reports Third Quarter 2016 Financial Results Nov 03 2016
Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016 Oct 27 2016
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Oct 11 2016
Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist Oct 11 2016
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sep 16 2016
Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under... Sep 07 2016
Q2 2016 Curis Inc Earnings Conference Call Aug 31 2016
View all press releases » Aug 04 2016
Curis Reports Second Quarter 2016 Financial Results Aug 04 2016
Curis to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016 Jul 28 2016
Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule... Jun 21 2016
Curis to Present at the Jefferies Healthcare Conference Jun 02 2016
Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting Jun 02 2016
Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally... Jun 01 2016
Q1 2016 Curis Inc Earnings Conference Call Jun 01 2016
View all press releases » May 09 2016
Curis Reports First Quarter 2016 Financial Results May 09 2016
Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016 May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)